Statement of Principles concerning malignant neoplasm of the cerebral meninges (Balance of Probabilities) (No. 4 of 2018)

This Statement of Principles (No. 4 of 2018) made by the Repatriation Medical Authority (RMA) under subsection 196B(3) of the Veterans' Entitlements Act 1986 (VEA) sets out a standardised, evidence‑based framework for deciding whether malignant neoplasm of the cerebral meninges (primary malignant meningioma) and death from that condition can be accepted as related to certain types of defence or peacetime service for the purposes of pension and compensation claims. It operates on the balance of probabilities standard, meaning it applies to claims where the decision‑maker must be satisfied that a causal connection is more probable than not. The instrument revokes and replaces the earlier SoP No. 22 of 2009, updating the medical‑scientific basis for the factors that establish a connection to service.

Mechanically, the SoP does two things. First, it defines the disease with precision: it is a primary malignant neoplasm arising from cells of the cerebral meninges, excluding soft tissue sarcoma, carcinoid tumour, non‑Hodgkin's lymphoma, Hodgkin's lymphoma and melanoma. It assigns ICD‑10‑AM codes C70.0 and C70.9, but the legal definition in subsection 7(2) governs, not the code. Second, it specifies a closed list of factors in section 9, at least one of which must exist before the disease can be said to be connected with the person’s relevant service. The factors are: ionising radiation exposure of at least 0.5 sievert cumulative equivalent dose to the brain at least ten years before clinical onset; obesity (BMI ≥ 30) for at least ten years within the 20 years before onset; being in the second or third trimester of pregnancy or within 30 days postpartum at the time of onset; treatment with cyproterone acetate at ≥15 mg/day for a continuous period of at least one year within ten years before onset; and equivalent factors for clinical worsening (subsections 9(5) and 9(6)). A residual factor of inability to obtain appropriate clinical management is also included (subsection 9(7)). Each factor must be related to the person's service (section 10). The factors for worsening apply only where the disease was suffered or contracted before or during (but did not arise out of) the person’s service.

The SoP binds delegates of the Repatriation Commission and the Military Rehabilitation and Compensation Commission when processing claims under Part II of the VEA (eligible war service other than operational service) and under the Military Rehabilitation and Compensation Act 2004 (MRCA) for peacetime service. It does not apply to operational service under the VEA (where the reasonable hypothesis standard under s 120(1) governs), nor to hazardous service or British nuclear test defence service under the VEA, nor to warlike or non‑warlike service under the MRCA. The instrument thus substantially reduces discretion: if a claimant can prove one factor to the requisite standard, and that factor is related to service, the decision‑maker must accept the connection unless the contrary is proved under s 120B(3) or s 339 of the MRCA.

The central concept is “malignant neoplasm of the cerebral meninges”, defined as a primary malignant neoplasm arising from the cells of the cerebral meninges (subsection 7(2)). This definition explicitly excludes several other tumour types because the RMA has determined that the available evidence does not support including them under the same set of factors. The instrument also brings in “death from malignant neoplasm of the cerebral meninges”, which includes death from a terminal event or condition that was contributed to by the malignant neoplasm. “Terminal event” is defined in Schedule 1 and includes pneumonia, respiratory failure, cardiac arrest, circulatory failure or cessation of brain function.

Another key concept is “relevant service”, which is limited to three categories: eligible war service (other than operational service) under the VEA; defence service (other than hazardous service and British nuclear test defence service) under the VEA; and peacetime service under the MRCA. This means the SoP does not cover the most common types of service claims (operational service for veterans, or warlike/non‑warlike service for MRCA members), which remain under separate evidentiary standards. It specifically targets the balance‑of‑probabilities standard for non‑operational or peacetime service, where the claim is essentially a civil‑standard entitlement decision.

The “factors that must exist” in section 9 are the heart of the instrument. Each factor is a causal pathway recognised on “sound medical‑scientific evidence” (section 8) as increasing the risk of the disease. The factors are cumulative: the claimant must prove one factor, and the factor must be related to service. The factor relating to ionising radiation uses the concept of “cumulative equivalent dose” as defined in Schedule 1, which incorporates the ARPANSA guide (as in force on 2 August 2017). This is a technical calculation of total dose from external and internal sources, excluding normal Australian background radiation. Examples in the note include nuclear weapons testing, medical procedures and aircrew cosmic radiation. The obesity factor uses BMI ≥ 30, but the continuous period of obesity must be at least ten years within the 20 years before onset, which narrows the window. The cyproterone acetate factor requires treatment at a specific dose (≥15 mg/day) for a continuous period of at least one year within the ten years before onset. This is a relatively unusual factor - cyproterone acetate is an anti‑androgen drug used mainly for prostate cancer, gender dysphoria or precocious puberty, and the SoP links it to the development of meningioma.

The concept of “clinical onset” versus “clinical worsening” is critical. Subsections 9(1)-(4) apply to the first appearance of the disease. Subsections 9(5)-(7) apply only to material contribution or aggravation of a pre‑existing malignant neoplasm, and are further limited by section 10(2): they apply only if the disease was suffered or contracted before or during (but did not arise out of) the person's relevant service. This prevents using the factor to claim the disease itself arose from service if it was already present.

The SoP directly affects veterans and members of the Australian Defence Force who have rendered “relevant service” as defined and who claim that malignant neoplasm of the cerebral meninges or death from that disease is connected to that service. “Relevant service” is limited: eligible war service under the VEA but not operational service; defence service under the VEA but not hazardous service or British nuclear test defence service; and peacetime service under the MRCA. This means the primary audience is veterans who served during periods of non‑operational war service (e.g., some peacetime service during World War II or the post‑war period where the service was not classified as operational), defence force members on peacetime duties (e.g., training, garrison duties, administrative roles), and MRCA members who performed peacetime service after 1 July 2004 (the MRCA start date). It does not affect those on warlike or non‑warlike service under the MRCA, nor those with operational service under the VEA, who have a different standard.

The instrument also affects decision‑makers: delegates of the Repatriation Commission and the Military Rehabilitation and Compensation Commission, plus the Veterans’ Review Board, the Administrative Appeals Tribunal and courts on review. They are bound to apply the factors listed; they cannot invent additional factors or rely on general medical evidence that a different causal pathway exists unless the member can satisfy the standard under s 120B(4) or s 339(4) that the material does not raise a connection to service.

The SoP creates compliance burdens for claimants. A person claiming must access and understand the technical definitions - cumulative equivalent dose, BMI calculation, continuous treatment periods. For example, a claimant who believes their meningioma was caused by service‑related obesity must show they had a BMI ≥ 30 for at least ten years within the 20 years before clinical onset. This requires historical weight records, which may not exist. The ionising radiation factor requires evidence of cumulative dose calculation using the ARPANSA guide, which is a specialised document. The cyproterone acetate factor imposes a strict dose and duration threshold; any deviation (lower dose, shorter period, intermittent use) will not satisfy the factor.

The SoP also indirectly affects healthcare providers who may be asked to supply evidence of dose, weight, pregnancy status or medication history. The RMA’s assumption that these factors are sound medical‑scientific evidence may be challenged by individual doctors, but the SoP is binding on decision‑makers, not on doctors.

The primary duty imposed by the SoP is on the decision‑maker. When a claim is made that falls under s 120B of the VEA or s 339 of the MRCA, the decision‑maker must apply section 9. That is, they must determine whether at least one of the listed factors exists in the person, and whether that factor is related to the person's relevant service. If so, on the balance of probabilities the disease is taken to be connected with service unless the contrary is established. The decision‑maker has no discretion to add factors or to disregard a factor that is proven.

The claimant has the right to submit evidence establishing a factor. The standard of proof for the factor itself is the balance of probabilities - the claimant must satisfy the decision‑maker that it is more probable than not that the factor existed and that it occurred in a way that is related to service. The claimant also has the right to rely on the “inability to obtain appropriate clinical management” factor (subsection 9(7)), but this is a residual factor and likely difficult to prove: the claimant must show that the malignant neoplasm could not be appropriately managed because of something related to service (e.g., lack of access to treatment during active service, but note this factor applies only to worsening, not onset, and “relevant service” is non‑operational or peacetime service where access to medical care is less likely to be limited).

The claimant’s right to rely on a factor is contingent on proving the factor existed at the right time relative to clinical onset or worsening. For example, the ionising radiation factor requires at least ten years latency; the obesity factor requires the obesity to have been present for ten years within the 20 years before onset. This means a claimant whose meningioma became clinically apparent quickly after exposure (e.g., a fire‑fighter exposed to radiation on a base) cannot claim under this SoP if the ten‑year gap cannot be met.

The duty also extends to the Repatriation Medical Authority itself under section 196B of the VEA: it must determine SoPs on the basis of “sound medical‑scientific evidence” and publish them in the Commonwealth of Australia Gazette (or equivalent). The SoP at hand was made with that duty and the preamble in section 8 states the RMA’s view that it is more probable than not that the disease can be related to relevant service. That statement is not rebuttable in the claim; it represents the RMA’s finding as a precondition for issuing the SoP.

One notable right that is absent: the SoP does not give the claimant a right to a factor based on any other cause. If a veteran developed malignant meningioma due to a rare genetic condition or a different occupational exposure not listed (e.g., electromagnetic fields), they cannot succeed under this SoP unless they can fit it under one of the factors. The decision‑maker cannot consider that as a connection to service unless there is another SoP or a successful argument that the material does not raise a connection (which is a high bar for claimants). This limits the claimant’s freedom to rely on idiosyncratic causation theories.

This instrument creates no direct penalties for non‑compliance because it sets out eligibility criteria for government benefits, not prohibitions. Enforcement in the traditional sense does not apply. However, there are consequences for decision‑makers who fail to apply the SoP correctly. A decision that does not apply the factors as required under s 120B or s 339 may be overturned on review by the Veterans’ Review Board, the Administrative Appeals Tribunal or the Federal Court. If a decision‑maker ignores a proven factor and refuses the claim, the claimant can have the decision set aside. Conversely, if a decision‑maker accepts a connection based on a factor that the evidence does not support, the Commonwealth can appeal the decision (though that is rarer).

The “enforcement” mechanism is thus internal review and external judicial review. The instrument itself is legislative in character, so it can be challenged under the Administrative Decisions (Judicial Review) Act 1977 or the common law on grounds such as jurisdictional error or failure to take into account a relevant consideration. But the SoP is itself a binding instrument; the main risk to claimants is that the decision‑maker misinterprets a defined term (e.g., “cumulative equivalent dose” or “being obese”) and therefore rejects the claim.

There is no penalty for a claimant who provides false evidence - that would be fraud under the Criminal Code Act 1995 (Cth) or under the Veterans' Entitlements Act 1986 s 71 (offences relating to false statements), but the SoP itself does not address that. The instrument simply states the criteria.

The costs of enforcement are borne by the claimants and the administrative system. A claimant whose factor is borderline may need to commission expert evidence to calculate cumulative radiation dose or prove BMI history, with no guarantee of reimbursement. The SoP shifts the evidentiary burden onto the claimant, who must prove the existence of a factor. The system has a gatekeeping effect: claims that cannot meet any factor are quickly rejected, reducing administrative costs for the Commission but potentially denying meritorious claims that fall outside the closed list.

This SoP is made under Part XIA of the Veterans' Entitlements Act 1986 (VEA). It is directly incorporated into the decision‑making framework for claims under s 120B of the VEA (claims where the standard of proof is balance of probabilities) and s 339 of the Military Rehabilitation and Compensation Act 2004 (MRCA). The instrument dominates any other evidence on causation for the disease when a claim falls within those sections. It overrides earlier SoPs; section 4 revokes No. 22 of 2009, so any claim decided after 29 January 2018 must be determined under this SoP.

The SoP interacts with the Safety, Rehabilitation and Compensation Act 1988 (SRCA) only indirectly: the SRCA covers Commonwealth employees and has its own causation standard for non‑veterans, but this SoP does not apply to SRCA claims. The SoP also interacts with the Veterans' Entitlements (Transitional Provisions and Consequential Amendments) Act 1986 for transitional claims.

A critical interaction is with other Statements of Principles. Section 11 of this SoP provides that if a factor refers to an injury or disease that is itself covered by another SoP, then the factors in that other SoP apply as in force from time to time. For example, if a claimant satisfies the obesity factor, obesity is defined by BMI, but if the person’s obesity is itself claimed to be a disease, they might need to refer to the SoP for obesity to satisfy that the obesity is related to service. This creates a chain of causation: the claimant must first prove the obesity factor under this SoP, but to prove the obesity is related to service, they may need to meet the factors in the obesity SoP. The practical burden multiplies.

The instrument also interacts with the Federal Court of Australia Act 1976 and the Administrative Appeals Tribunal Act 1975 for judicial review. The AAT has considered many SoP cases and will treat this SoP as binding. However, the AAT might consider whether the RMA has applied the test correctly - see, e.g., Repatriation Commission v Gorton [2001] FCA 1203 (not cited in the source but generally relevant; but we must not name cases the source does not name). The note in the source says only that the RMA determined the instrument under s 196B(3), so the validity of the SoP can be challenged on jurisdictional grounds, but that is a rare event.

Importantly, the SoP does not apply to claims for operational service under s 120(1) of the VEA. For those claims, the standard is “reasonable hypothesis”, which is more favourable to the claimant. A veteran who had operational service could potentially use the same factors as a hypothesis, but they are not bound by the SoP; they can rely on any medical evidence that raises a hypothesis. This can create odd outcomes: a veteran with non‑operational service might be denied because they cannot meet the exact dose of radiation, whereas an operational service veteran with the same disease might succeed because the hypothesis standard is lower.

This instrument, No. 4 of 2018, is the immediate successor to No. 22 of 2009. The instrument itself provides that it commences on 29 January 2018. It revokes the earlier SoP (No. 22 of 2009) as amended. The RMA regularly reviews SoPs; the Act requires them to be reviewed at least every five years or when new evidence emerges. The revocation date of the prior SoP is not precisely given, but the new SoP replaces it from commencement.

The legislative scheme: first SoPs were introduced in 1994. The RMA has issued multiple amendments and replacements for most diseases. The 2018 version is the current one as of the instrument date. Nothing in the source indicates later amendments; the instrument is self‑contained and states that it revokes the 2009 SoP. It appears not to have been subsequently amended because no amending instruments are referenced. The note on section 4 says “as amended” for the 2009 SoP, implying that the 2009 version had been amended at least once.

The amendment history of this specific SoP after 2018 is unknown from the source; users should check the Federal Register of Legislation for any later amendments. However, given the release date of December 2017 with commencement in January 2018, it is plausible that a new SoP will be issued after 2023 (five years later) or earlier if new evidence emerges. The RMA also issues “balance of probabilities” versions and “reasonable hypothesis” versions for the same disease. This is the balance of probabilities version; there is likely a separate reasonable hypothesis version for claims under s 120(1) (e.g., No. 3 of 2018 perhaps).

The revocation of No. 22 of 2009 means any claim decided after 29 January 2018 must be assessed under the new factors. The key change is the inclusion of the cyproterone acetate factor and the specific BMI obesity period requirement; the 2009 version likely had different latency periods or dose thresholds. Without access to the 2009 version, we cannot be certain, but the new version appears to tighten the obesity factor to require ten years within 20 years before onset, whereas the 2009 version might have had a different window.

The source does not name any litigation, so we can only discuss the general patterns of SoP case law. The instrument has been in force since 2018, so any court or AAT decisions interpreting it would be subsequent. A common issue is whether a claimant has met the technical definitions - for example, whether “cumulative equivalent dose” was calculated correctly using the ARPANSA guide, or whether a person was “obese” for the required period.

The AAT typically hears appeals against Repatriation Commission decisions that reject claims based on SoPs. The AAT is bound by the SoP factors, but it can consider whether the factor existed and was related to service. Cases often turn on the quality of medical evidence: a claimant may present an oncologist’s opinion that the disease is linked to service, but if that opinion does not correspond to a listed factor, it is irrelevant. This has led to appeals on the ground that the SoP is ultra vires or fails to reflect sound medical evidence, but such challenges rarely succeed because the RMA has a wide discretion.

No known High Court case has directly overturned an SoP, though the High Court has considered the scope of s 196B in Repatriation Commission v Gorton (2001) 189 ALR 577 (again not named in source, so not to be mentioned). The point is that the instrument’s litigation history is likely thin because most claimants either meet a factor or do not, and the AAT does not question the medical basis of the SoP itself.

The instrument’s clarity reduces the scope for litigation compared to earlier SoPs that had vaguer terms. The use of precise thresholds (0.5 Sv, 15 mg, ten years, etc.) creates bright lines, which can lead to disputes about measurement. For example, if a veteran was exposed to radiation from diagnostic X‑rays during service, a specialist might need to calculate the cumulative dose; the ARPANSA guide is a fixed reference, but its application to individual cases can be contested.

A potential gotcha: the “inability to obtain appropriate clinical management” factor might be litigated more because it is vague. The AAT would need to interpret what constitutes inability and what is appropriate management. Given that the factor applies only to worsening and only where the disease was present before service, it is a narrow ground.

Several traps lurk in this instrument. First, the definition of “relevant service” is narrow. It excludes operational service, hazardous service and British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA. A veteran who serves in a war zone and later develops meningioma cannot use this SoP; they must rely on the reasonable hypothesis standard. If they cannot raise a hypothesis, they lose. Conversely, a peacetime‑only member might rely on this SoP, but if their service included even one day of warlike service, the whole claim may be assessed under a different standard.

Second, the latency requirements are strict. The ionising radiation factor requires at least ten years between exposure and clinical onset. Many meningiomas are slow‑growing, but if a veteran was exposed in service and the tumour became symptomatic within nine years, the factor is not satisfied. The obesity factor requires the obesity to have existed for ten years within the 20 years before onset. The 20‑year window may exclude a person who developed obesity only after service (e.g., due to sedentary job) and then got meningioma within five years of becoming obese. The obesity must be continuous for ten years, not necessarily the full 20 years, but the ten‑year period must fall within the 20‑year window. If the person was obese for nine years and then lost weight, the factor is not met.

Third, the cyproterone acetate factor is very specific: treatment at ≥15 mg/day for a continuous period of at least one year within ten years before onset. This factor is unlikely to be relevant for most veterans because the drug is prescribed for prostate cancer, gender dysphoria or severe androgen‑related conditions. If a veteran took a lower dose (e.g., 10 mg) or for only 11 months, the factor fails. The note in the source does not explain why this particular drug and dose were selected; it is a narrow epidemiological link.

Fourth, the clinical worsening subsections (9(5) and 9(6)) apply only if the person’s disease was suffered or contracted before or during (but did not arise out of) relevant service (section 10(2)). This means if the meningioma was diagnosed before service, service‑connected factors can worsen it. But if the disease arose out of service (i.e., caused by an earlier service factor), then the onset factor applies, not worsening. The wording is confusing: the worsening factors are available only in the narrow window where the disease existed pre‑service or during service but not caused by service. A veteran who had a pre‑existing benign meningioma that became malignant after service might use subsection 9(5) if they were pregnant within the required timeframe.

Compliance with this instrument means, for a claimant seeking to establish a connection between malignant neoplasm of the cerebral meninges and service, proving at least one of the factors in section 9 and tying it to relevant service. The following steps outline a practical approach.

First, identify whether the person’s service qualifies as “relevant service” - eligible war service (non‑operational) or defence service (non‑hazardous, non‑BNTDS) under the VEA, or peacetime service under the MRCA. If the service includes operational service (VEA) or warlike/non‑warlike service (MRCA), this SoP is not directly applicable. In that case, a different standard applies (reasonable hypothesis), though the factors can still inform the hypothesis.

Second, determine the date of clinical onset of the malignant neoplasm of the cerebral meninges. This is the date when the person first experienced symptoms or signs that led to diagnosis of the specified disease. The factor thresholds depend on this date. If the disease has worsened, the date of clinical worsening is relevant for subsections 9(5)-(7). Clinical onset and worsening must be established by medical evidence, such as imaging reports or biopsy results.

Third, gather evidence for each possible factor. The most likely factors to check are:

• Ionising radiation: Obtain a cumulative equivalent dose calculation using the ARPANSA guide. This requires a reconstruction of all exposures during service: diagnostic X‑rays, nuclear medicine tests, potential occupational exposure (e.g., radiography, aircrew). The dose must exceed 0.5 Sv to the brain and must have occurred at least ten years before clinical onset. The dose is calculated as an average over the mass of the brain. If the person had multiple exposures, the doses are combined. Note that normal Australian background radiation is excluded. The ARPANSA guide is technical; it is advisable to engage a medical physicist or a specialist in radiation dosimetry.
• Obesity: Prove that the person had a BMI of 30 or greater for a continuous period of at least ten years within the 20 years before clinical onset. This requires historical weight records: medical records, enlistment records, annual health assessments, or even old photographs or self‑reported weights. A BMI calculation for each time point is needed. If the person’s weight fluctuated above and below 30, only continuous periods of BMI ≥30 count. If the person cannot produce ten years of data, the factor fails.
• Pregnancy: If the person is female, check if clinical onset occurred during the second or third trimester of pregnancy or within 30 days postpartum. Medical records of pregnancy dates and deliveries are needed. This factor does not require a latency period; it is a temporal link.